- Home
- AYI vs ROIV Comparison
AYI vs ROIV Comparison
Compare AYI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYI
- ROIV
- Stock Information
- Founded
- AYI 2001
- ROIV 2014
- Country
- AYI United States
- ROIV United Kingdom
- Employees
- AYI N/A
- ROIV N/A
- Industry
- AYI Building Products
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- AYI Consumer Discretionary
- ROIV Health Care
- Exchange
- AYI Nasdaq
- ROIV Nasdaq
- Market Cap
- AYI 8.4B
- ROIV 7.8B
- IPO Year
- AYI N/A
- ROIV N/A
- Fundamental
- Price
- AYI $298.73
- ROIV $11.40
- Analyst Decision
- AYI Hold
- ROIV Buy
- Analyst Count
- AYI 5
- ROIV 4
- Target Price
- AYI $340.60
- ROIV $17.50
- AVG Volume (30 Days)
- AYI 395.9K
- ROIV 7.9M
- Earning Date
- AYI 06-26-2025
- ROIV 08-07-2025
- Dividend Yield
- AYI 0.23%
- ROIV N/A
- EPS Growth
- AYI 3.17
- ROIV N/A
- EPS
- AYI 12.69
- ROIV N/A
- Revenue
- AYI $4,168,800,000.00
- ROIV $29,053,000.00
- Revenue This Year
- AYI $14.58
- ROIV $3.28
- Revenue Next Year
- AYI $8.88
- ROIV $156.84
- P/E Ratio
- AYI $23.32
- ROIV N/A
- Revenue Growth
- AYI 9.16
- ROIV N/A
- 52 Week Low
- AYI $216.81
- ROIV $8.73
- 52 Week High
- AYI $345.30
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- AYI 59.03
- ROIV 54.55
- Support Level
- AYI $301.08
- ROIV $10.71
- Resistance Level
- AYI $309.90
- ROIV $11.58
- Average True Range (ATR)
- AYI 6.84
- ROIV 0.29
- MACD
- AYI -0.35
- ROIV 0.00
- Stochastic Oscillator
- AYI 65.76
- ROIV 62.16
About AYI Acuity Brands Inc.
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.